

RECEIVED
CENTRAL FAX CENTER
FEB 16 2007

inflammatory marker or monitoring a leukotriene level before and during administration of the composition. Applicants hereby elect the step of monitoring a leukotriene level for examination in the above-identified application. Claims 216 and 217 recite the step of monitoring a leukotriene level before and during administration of the composition. Claims 206, 208, 209, 211-213 and 225 generically encompass the elected species.

The Examiner stated that the pending claims encompass multiple different methods of selecting a subject. Applicants hereby elect the species of selecting a subject by determining a FLAP genotype or haplotype for examination in the above-identified application. Claim 225 recite the species of selecting a subject by determining a FLAP genotype or haplotype. Claims 206, 208, 209, 211-213, 216 and 217 generically encompass the elected species.

CONCLUSION

Applicants the pending claims are in condition for allowance and early notice thereof is requested.

Dated: February 16, 2007

Respectfully submitted,

By 

Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant